Poznan

• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib … Halted
  2024-516672-16-00 5 2024-02-02 Multiple Sclerosis
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended
  2024-513435-24-01 4 2025-06-03 Neuropathic Pain; Distal Sensory Polyneuropathy
• A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP Ended
  2024-518364-12-00 4 2025-05-09 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 … Ended
  2024-517404-11-00 5 2025-04-30 Knee Osteoarthritis
• A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder … Ended
  2024-511549-20-00 4 2025-04-22 Dermatitis atopic
• A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity Ended
  2024-513679-42-00 4 2025-04-09 Obesity
• A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in … Ended
  2024-510826-16-00 5 2025-04-07 Rheumatoid Arthritis
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended
  2023-508337-14-00 4 2025-03-18 Myositis, Dermatomyositis
• A proof-of-concept study of lunsekimig compared with placebo in adults with chronic rhinosinusitis with nasal polyps Ended
  2024-511261-11-00 4 2025-03-05 Respiratory tract diseases
• Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M … Ended
  2024-512562-34-00 4 2025-02-24 Type 2 Diabetes Mellitus
• Open-Label Extension of EryDex in A-T (OLE NEAT) Ended
  2024-513618-37-00 5 2024-12-23 Ataxia Telangiectasia (A-T)
• A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118 … Ended
  2024-514981-37-00 4 2024-12-05 Rheumatoid Arthritis
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a … Ended
  2024-513104-34-00 4 2024-11-25 Major Depressive Disorder
• Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome Ended
  2024-515060-32-00 5 2024-11-22 Takotsubo syndrome
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi … Ended
  2023-506664-14-00 5 2024-10-24 Rheumatoid Arthritis
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509198-22-00 5 2024-10-21 Thyroid Eye Disease (TED)

Showing 673–696 of 914 trials